Article Information
PubMed
Published By
Online ISSN
History
- Received March 31, 2020
- Revision received May 13, 2020
- Accepted May 14, 2020
- Published online May 28, 2020.
Copyright & Usage
© 2020 van der Lelij et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
Author Information
- Petra van der Lelij1,*,
- Joseph A Newman2,*,
- Simone Lieb3,*,
- Julian Jude1,*,
- Vittorio Katis2,
- Thomas Hoffmann1,
- Matthias Hinterndorfer1,
- Gerd Bader3,
- Norbert Kraut3,
- Mark A Pearson3,
- Jan-Michael Peters1,4,
- Johannes Zuber1,4⇑,
- Opher Gileadi2⇑ and
- Mark Petronczki3⇑
- 1Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria
- 2Structural Genomics Consortium, University of Oxford, Oxford, UK
- 3Boehringer Ingelheim Regional Center Vienna (RCV) GmbH & Co KG, Vienna, Austria
- 4Medical University of Vienna, VBC, Vienna, Austria
- Correspondence: johannes.zuber{at}imp.ac.at
- opher.gileadi{at}sgc.ox.ac.uk
- mark_paul.petronczki{at}boehringer-ingelheim.com
↵* Petra van der Lelij, Joseph A Newman, Simone Lieb, and Julian Jude contributed equally to this work
Funding
European Research Council
GA 693949J-M PetersHuman Frontier Science Program
RGP0057/2018J-M PetersWellcome
106169/ZZ14/ZO GileadiInnovative Medicines Initiative (European Union-EU/European Federation of Pharmaceutical Industries and Associations-EFPIA)
115766O GileadiEuropean Community’s Seventh Framework Programme
FP7/2007-2013J ZuberEuropean Research Council
ERC PoC GA 862507J ZuberAustrian Science Fund, FWF
GA SFB F47J ZuberAbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada
1097737Janssen, Merck KGaA Darmstadt Germany, MSD, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP, Takeda